trending Market Intelligence /marketintelligence/en/news-insights/trending/o9DzF2jX3z0oVani4ii7BA2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

NatureWise Biotech & Medicals H1 loss widens 33.2% YOY


ESG hits the mainstream for European private equity sponsors


What’s the Bottom Line: Credit Impact of COVID-19 on US Municipals


Banking Essentials Newsletter - February Edition, Part 2


Episode 1: Origins of 451 Research - Part 1

NatureWise Biotech & Medicals H1 loss widens 33.2% YOY

NatureWise Biotech & Medicals Corp. said its normalized net income for the first half was a loss of 43 Taiwan cents per share, compared with a loss of 33 cents per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was a loss of NT$15.2 million, compared with a loss of NT$11.4 million in the prior-year period.

Total revenue grew on an annual basis to NT$24.4 million from NT$23.3 million, and total operating expenses climbed 28.5% from the prior-year period to NT$52.6 million from NT$40.9 million.

Reported net income totaled a loss of NT$20.9 million, or a loss of 60 cents per share, compared to a loss of NT$18.2 million, or a loss of 52 cents per share, in the year-earlier period.

As of Aug. 12, US$1 was equivalent to NT$31.39.